LisaShing-E LuWangMD

Oncology • Whittier, CA

Hematologist/Oncologist at PIH Health

Join to view full profile

Dr. Wang is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Wang's full profile

Already have an account?

Office
12462 Putnam St
Ste 206
Whittier, CA 90602
Phone+1 562-789-5480

Fax+1 562-789-5954
Is this information wrong?

Summary

Hematologist/Oncologist at PIH Health in Whittier, CA.

Education & Training

Los Angeles County-Harbor-UCLA Medical Center 1Fellowship, Hematology and Medical Oncology, 2008 - 2011
Olive View/UCLA Medical CenterResidency, Internal Medicine, 2005 - 2008
Chicago Medical School at Rosalind Franklin University of Medicine and ScienceClass of 2005, MD
Northwestern UniversityBS

Certifications & Licensure

CA State Medical License 2006 - 2024
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Clinical Trials

Comparison of Axillary Lymph Node Dissection With Axillary Radiation for Patients With Node-Positive Breast Cancer Treated With Chemotherapy Start of enrollment: 2014 Feb 07
Active, not recruiting
Phase 3
Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer Start of enrollment: 2014 Jul 08
Completed
Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial) Start of enrollment: 2014 Sep 26
Recruiting
Not Applicable
Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial) Start of enrollment: 2015 Mar 23
Recruiting
Phase 3
Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches Start of enrollment: 2014 Nov 01
Completed
Phase 2
Lung-MAP: Palbociclib as Second-Line Therapy in Treating Cell Cycle Gene Alteration Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer Start of enrollment: 2014 Sep 01
Completed
Phase 2, Phase 3
Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers Start of enrollment: 2015 Dec 29
Active, not recruiting
Phase 3
Join now to see all

Publications & Presentations

PubMed

5 citations
Patient self-reporting of tolerability using PRO-CTCAE in a randomized double-blind, placebo-controlled phase II trial comparing gemcitabine in combination with adavos...
Ainhoa Madariaga, Sandra A Mitchell, Tyler Pittman, Lisa Wang, Valerie Bowering, Nisan Kavak, Judy Quintos, Karen Chang, Janelle Ramsahai, Katherine Karakasis, Stephen...> ;Gynecologic Oncology. 2022 Nov 1
23 citations
Translational randomized phase II trial of cabozantinib in combination with nivolumab in advanced, recurrent, or metastatic endometrial cancer.
Stephanie Lheureux, Daniela E Matei, Panagiotis A Konstantinopoulos, Ben X Wang, Ramy Gadalla, Matthew S Block, Andrea Jewell, Stephanie L Gaillard, Michael McHale, Ca...> ;Journal for Immunotherapy of Cancer. 2022 Mar 1

Press Mentions

Sister Serves as Surrogate of Twins for Other Sister Who Had Breast CancerFebruary 7th, 2017

Professional Memberships

American Society of Clinical Oncology - ASCO
Member
American Society of Hematology - ASH
Member

Other Languages

Chinese (Mandarin)

Hospital Affiliations

PIH Health Whittier HospitalWhittier, California